Answers are grounded in this paper and cite their sources.
Vitamin D is a neurosteroid hormone that may be involved in cognition in older adults.1-3 Supporting epidemiological evidence is primarily based on cross-sectional studies, and the lack of placebo-controlled intervention studies prevents inferring a causal relationship.4 In particular, the single pre–post study on this topic found no effect of vitamin D2 supplementation on cognition in institutionalized older adults.5 However, the use of vitamin D2 supplements, which are less effective than D3 for repletion;6 a 4-week follow-up, which might have been too short to capture any treatment effect;3 and the failure to assess executive functions, even if these domain-specific cognitive functions seem related to vitamin D status,7, 8 limited that study. The objective of the current study was to examine in a pre–post design the medium-term effects of vitamin D3 supplementation on cognition, in particular on executive functions, in elderly outpatients visiting a memory clinic. All outpatients with no recent vitamin D supplementation and no prescription of antidementia drugs (anticholinesterasics or memantine) who visited the University Memory Centre of Angers, France, twice between June 2009 and October 2011 and gave informed consent for research were enrolled in this retrospective pre–post cohort study. The prescription of oral vitamin D3 during the first consultation, whatever the reason, was noted from the hospital prescription records (800 IU/d or 100,000 IU/month). Except for patients who were autonomous, a nurse dispensed D3 supplements to ensure adherence to treatment. Global cognitive function was assessed at baseline and follow-up visits using the Mini-Mental State Examination (MMSE, total score of 30) and the Cognitive Assessment Battery (CAB, total score of 96),9 and executive functions were assessed using the Frontal Assessment Battery (FAB, total score of 18).10 The score change on each cognitive test was calculated from the formula: score after treatment – score before treatment. Some of the patients had serum 25-hydroxyvitamin D (25OHD) levels measured at baseline and follow-up visits (Table 1). Multiple regression models were performed to examine associations between use of vitamin D3 supplements and change on each cognitive score. Age, sex, cognitive score at baseline and between-visit time were used as covariates. P < .05 was considered statistically significant. All analyses were performed using SPSS, version19.0, (SPSS, Inc., Chicago, IL). The study was conducted in accordance with the ethical standards set forth in the Declaration of Helsinki (1983). The local ethical committee of Angers approved the entire study protocol. Of 44 outpatients included (median age 80.6, interquartile range 14.0; 54.5% female; 100% Caucasian), 20 received vitamin D3 supplements. There was no difference between the vitamin D3 and control groups at baseline, especially regarding cognitive scores and serum 25OHD concentration (Table 1). After 16 months of follow-up, the vitamin D3 group had higher 25OHD concentrations than at baseline (P = .001) and higher than those of the control group (P < .001). The vitamin D3 group had also higher final scores on the MMSE, CAB, and FAB than the control group and greater score changes on each cognitive test (Table 1). In particular, in the vitamin D3 group, an improvement of FAB score accompanied the increase in 25OHD concentration (P = .02). Vitamin D supplementation was associated with score change on the MMSE (adjusted β = 2.23, 95% confidence interval (CI) = 0.38–4.07, P = .02), the CAB (adjusted β = 5.55, 95% CI = 0.64–10.47, P = .03), and the FAB (adjusted β = 1.85, 95% CI = 0.30–3.39, P = .02). Vitamin D supplementation was also associated with improvement in MMSE (odds ratio (OR) = 3.80, 95% CI = 1.02–14.21, P = .047), CAB (OR = 16.50, 95% CI = 2.51–108.60, P = .004), and FAB (OR = 8.00, 95% CI = 1.52–42.04, P = .01) scores. The use of vitamin D3 supplements, irrespective of potential confounders, was associated with medium-term improvement in cognitive performance in older adults and in particular with better executive functioning. The present pre–post study used vitamin D3 supplements over a longer period than a previous study,5 which may explain why a treatment effect was captured. Additionally, the control group in the previous study may have received vitamin D routinely during follow-up (mean 25OHD stable at approximately 34 ng/mL), whereas the control group in the current study was not taking any vitamin D supplements, as illustrated by the decrease in 25OHD concentration during follow-up (Table 1). With this design, the effect of receiving vs not receiving vitamin D supplements and, indirectly, the effect of increasing vs decreasing 25OHD concentrations was captured. Finally, an improvement was also found in executive functions after vitamin D3 supplementation. This is concordant with previous studies suggesting that brain structures underlying executive functions are the target of neuroprotective and vasculoprotective properties of vitamin D.1, 3, 7, 8 Nevertheless, the pre–post design of the current study without randomization limits the exploration of the cognitive effect of vitamin D repletion. Placebo-controlled randomized clinical trials are needed to corroborate these results with higher levels of evidence. The authors wish to thank Angers University Hospital for technical support. Conflict of Interest: Dr. Annweiler serves as an unpaid consultant to Ipsen Pharma company. He has no relevant financial interest in this manuscript. Prof. Beauchet serves as an unpaid consultant for Ipsen Pharma company and as a board member for Gériatrie, Psychologie et Neuropsychiatrie du Vieillissement. He has no relevant financial interest in this manuscript.
No takes yet. Share an insight, caveat, or question.
Annweiler et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: